(PharmaNewsWire.Com, July 01, 2017 ) Recombinant hirudin is known to be a potent thrombin-specific inhibitor resulting from the natural hirudin of the leech. Over the years, the demand for this inhibitor has risen due to the rise in number of patients suffering from thrombosis disease. To cover the market status, a fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “Global Recombinant Hirudin Market Research Report 2017”, which includes data about the key regions active in the production of recombinant hirudin. Moreover, the report also reveals growth of the sector at a double-digit CAGR during the period 2017-2022.
Presently, the market for recombinant hirudin is growing due to its applications in the medical sector. This medicine is needed for the treatment of tumor disease, which surges its market importance on the global level. Depending on the product variety, recombinant hirudin is available in a number of versions depending on the dosage, such as 12000 ATU / mg, 95% and 16000 ATU / mg, 95%. Furthermore, manufacturers like Abbott, Teva Pharmaceutical Industries Ltd, The Medicines Company, Pfizer, Inc and Pentapharm, contribute heavily to the development of the recombinant hirudin market.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Recombinant Hirudin in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India
Global Recombinant Hirudin market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Abbott
The Medicines Company
Teva Pharmaceutical Industries Ltd
Pfizer, Inc
Pentapharm
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
12000 ATU / mg, 95%
16000 ATU / mg, 95%?
16000 ATU / mg, 98%?
Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Recombinant Hirudin for each application, including
Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
